ASP2535

Last updated
ASP2535
ASP2535.svg
Names
IUPAC name
4-[3-(6-phenylpyridin-3-yl)-5-propan-2-yl-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole
Identifiers
3D model (JSmol)
ChEMBL
PubChem CID
UNII
  • InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3
    Key: FQGLDGKVKDPVLO-UHFFFAOYSA-N
  • CC(C)C1=NN=C(N1C2=CC=CC3=NON=C32)C4=CN=C(C=C4)C5=CC=CC=C5
Properties
C22H18N6O
Molar mass 382.427 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

ASP2535 is an inhibitor of the type 1 glycine transporter. [1] It could potentially be used in treatment of Alzheimer's disease and schizophrenia.

Potential uses

ASP2535 has been investigated for the treatment of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent. [1]

References

  1. 1 2 Harada, Katsuya; Nakato, Kazuhiro; Yarimizu, Junko; Yamazaki, Mayako; Morita, Masahiko; Takahashi, Shinji; Aota, Masaki; Saita, Kyoko; Doihara, Hitoshi; Sato, Yuichiro; Yamaji, Takayuki; Ni, Keni; Matsuoka, Nobuya (2012-06-15). "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease". European Journal of Pharmacology. 685 (1–3): 59–69. doi:10.1016/j.ejphar.2012.04.013. ISSN   1879-0712. PMID   22542656.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.